DGAP-News: STADA Arzneimittel AG: Good result despite

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: STADA Arzneimittel AG: Good result despite challenging framework conditions - Group sales rise by 4 percent - significant increase of adjusted EBITDA by 12 percent and adjusted net income by 36 percent - outlook for 2014 confirmed

DGAP-News: STADA Arzneimittel AG / Key word(s): 9-month figures STADA Arzneimittel AG: Good result despite challenging framework conditions - Group sales rise by 4 percent - significant increase of adjusted EBITDA by 12 percent and adjusted net income by 36 percent - outlook for 2014 confirmed 13.11.2014 / 07:25 --------------------------------------------------------------------- Important items at a glance - Group sales rise to Euro 1,482.7 million (+4 percent) - adjusted for currency and portfolio effects it decreases slightly by 1 percent - Good sales development in Central Europe - still difficult business environment in Russia - Despite the difficult market environment, particularly in Russia, and high burdens from currency translation effects of Euro 19.2 million before tax due to the fluctuation of the Russian ruble as well as further significant currencies of the market region CIS / Eastern Europe, reported EBITDA rises by 10 percent - adjusted EBITDA sees growth by 12 percent - Reported net income rises by 10 percent despite high special effects - adjusted net income records strong growth by 36 percent - The earnings figures include a positive effect on earnings of Euro 15.9 million before and approximately Euro 11 million after taxes resulting from a change in the defined benefit plan for the Chairman of the Executive Board, which had been planned for a long time and implemented in August. STADA key figures <pre> 1-9/2014 1-9/2013 +/- Group sales Euro 1,482.7 million Euro 1,426.2 million +4% EBITDA, reported Euro 293.6 million Euro 267.0 million +10% EBITDA, adjusted Euro 316.2 million Euro 283.5 million +12% Net income, reported Euro 99.1 million Euro 90.2 million +10% Net income, adjusted Euro 136.1 million Euro 100.3 million +36% Earnings per share Euro 1.64 Euro 1.52 +8% Earnings per share, adjusted Euro 2.25 Euro 1.69 +33% </pre> Bad Vilbel, November 13, 2014 - In the first nine months of 2014, STADA's business development was within the scope of expectations. On the one hand, the Group was confronted by challenging framework conditions in the two market regions of Germany and CIS / Eastern Europe. On the other, it was burdened by one-time special effects in connection with currency effects recorded in the income statement in the total amount of Euro 19.2 million before or Euro 15.8 million after taxes, which resulted from the fluctuation of the Russian ruble as well as other significant currencies of the market region CIS / Eastern Europe. "We are very satisfied with the 51 percent that branded products contributed to the adjusted operating profit of both core segments. In the course of the introduction of a centralized portfolio management structure and decentralized marketing, we will increasingly utilize synergies in these areas and be able to further expand this share", said Hartmut Retzlaff, Chairman of the Executive Board of STADA Arzneimittel AG. Development of sales Group sales in the first nine months of 2014 increased by 4 percent to Euro 1,482.7 million (1-9/2013: Euro 1,426.2 million). Sales of the core segment Generics slightly decreased by 1 percent to Euro 884.2 million in the reporting period (1-9/2013: Euro 895.8 million) - primarily due to the development in the markets of Germany and Russia. Generics thus contributed 59.6 percent to Group sales (1-9/2013: 62.8 percent). Sales of the core segment Branded Products recorded substantial growth of 13 percent to Euro 565.8 million in the first three quarters of 2014 (1-9/2013: Euro 499.5 million). Branded products thereby contributed 38.2 percent to Group sales (1-9/2013: 35.0 percent). Development of earnings Reported operating profit was slightly above the level of the corresponding period of the previous year with Euro 185.5 million (1-9/2013: Euro 184.9 million). Reported EBITDA rose by 10 percent to Euro 293.6 million (1-9/2013: Euro 267.0 million). Reported net income recorded an increase of 10 percent to Euro 99.1 million (1-9/2013: Euro 90.2 million). This development was positively influenced by earnings in the amount of Euro 15.9 million before and approximately Euro 11 million after taxes resulting from a change in the defined benefit plan for the Chairman of the Executive Board, which had been planned for a long time and implemented in August. After adjusting the key earnings figures for influences distorting the period comparison resulting from one-time special effects, adjusted operating profit increased by 15 percent in the first three quarters of 2014 to Euro 232.6 million (1-9/2013: Euro 202.1 million). Adjusted EBITDA recorded an increase of 12 percent to Euro 316.2 million (1-9/2013: Euro 283.5 million). Net income, adjusted for one-time special effects and effects from the measurement of derivative financial instruments under financial income and expenses, showed substantial growth of 36 percent to Euro 136.1 million (1-9/2013: Euro 100.3 million). The disproportionate increase in net profit can primarily be attributed to a substantial reduction of the effective tax rate as of the first quarter of 2014. This development results from a changed profit allocation in the STADA Group, which has been primarily influenced by the successful conclusion of the "STADA - build the future" project at the end of financial year 2013 and a connected adjustment of the internal transfer pricing model. As a consequence, STADA Arzneimittel AG has been using, among other things, tax interest carryforwards in Germany since the beginning of the current financial year, which resulted from applying the regulations in connection with the so-called interest barrier in previous periods. In view of this, the adjusted effective tax rate for the first nine months of 2014 decreased to 22.9 percent in comparison to the corresponding period of the previous year (1-9/2013: 34.7 percent). The reported tax rate decreased to 25.1 percent as compared to the corresponding period of the previous year (1-9/2013: 35.5 percent). The net debt to adjusted EBITDA ratio was at 3.4 in the reporting period (1-9/2013: 3.7). Development of the market regions The four STADA market regions recorded varying developments in the first nine months of 2014. In market region Germany, sales increased slightly by 1 percent. In Central Europe, sales recorded a significant rise of 14 percent. In CIS / Eastern Europe, sales applying the exchange rates of the previous year declined by 2 percent, whereas sales in Euro declined by 13 percent as a result of negative currency effects. In market region Asia & Pacific, sales increased by a significant 59 percent. In the market region Germany, sales increased slightly by 1 percent to Euro 341.6 million in the first nine months of 2014 (1-9/2013: Euro 336.7 million). This development was due to opposing factors. The still decreasing generics sales in this market region as a result of the continuing difficult local framework conditions stood in opposition to rising sales both in the branded products business as well as the export activities. This market region contributed a total of 23.0 percent to Group sales (1-9/2013: 23.6 percent). In the market region Central Europe, sales increased substantially by 14 percent to Euro 691.0 million in the first three quarters of 2014 (1-9/2013: Euro 607.8 million). This pleasing development is especially attributable to sales growth in the United Kingdom by a significant 107 percent - predominantly due to the purchase of the British OTC supplier Thornton & Ross (adjusted +2 percent) -, as well as in Italy by 5 percent, in Belgium by 8 percent and in Spain by 8 percent, and took place despite a high comparable basis of the corresponding period of the previous year. Sales generated in this market region had a share of 46.6 percent of Group sales (1-9/2013: 42.6 percent). In market region CIS / Eastern Europe, sales in the first nine months of the current financial year applying the exchange rates of the previous year declined by 2 percent. In euro, sales decreased by 13 percent to Euro 384.2 million as a result of negative currency effects (1-9/2013: Euro 440.3 million). Sales in this market region thus contributed 25.9 percent to Group sales (1-9/2013: 30.9 percent). In Russia, sales declined by 9 percent in the first three quarters of 2014 applying the exchange rates of the previous year. As a result of a clearly negative currency effect of the Russian ruble, sales declined in euro strongly by 19 percent to Euro 236.1 million (1-9/2013: Euro 292.1 million). Sales in Serbia increased in the reporting period by 13 percent applying the exchange rates of the previous year. In euro, sales showed growth by 10 percent to Euro 67.9 million as a result of a negative currency effect of the Serbian dinar (1-9/2013: Euro 61.6 million). In the market region Asia & Pacific, sales in the first nine months of the current financial year increased substantially by 59 percent to Euro 66.0 million (1-9/2013: Euro 41.4 million). This market region's contribution to Group sales amounted to 4.5 percent (1-9/2013: 2.9 percent). The pleasing development was predominately attributable to sales growth resulting from the consolidations of the Vietnamese company STADA Vietnam J.V. Co., Ltd. and the Chinese company STADA Pharmaceuticals Beijing Ltd. as subsidiaries (adjusted -9 percent). Development, production and procurement Research and development costs amounted to Euro 44.4 million in the reporting period (1-9/2013: Euro 39.6 million). Worldwide, STADA launched a total of 459 individual products in the individual national markets in the first three quarters of 2014 (1-9/2013: 508 product launches). Outlook The Executive Board confirms the outlook for financial year 2014. According to this, STADA expects slight growth in Group sales, adjusted EBITDA and adjusted net income. For reasons of transparency, the adjustments as from 2014 include currency translation effects recorded in the income statement from the fluctuation of the Russian ruble as well as further significant currencies of the market region CIS / Eastern Europe and burdens from additional impairments and other measurement effects due to purchase price allocations as well as significant product acquisitions taking financial year 2013 as basis. STADA adjustments <pre> 1-9/2014 Net income, reported Euro 99.1 million One-time effects Burden from currency effects recorded in the income statement Euro resulting from the fluctuation of the Russian ruble as well as +15.8 further significant currencies of the market region CIS / Eastern million Europe Burden from additional impairments and other measurement effects Euro due to purchase price allocations as well as significant product +10.7 acquisitions taking financial year 2013 as basis million Burden from value adjustments netted of write-ups on intangible Euro assets after impairment tests +10.2 million Burden from several extraordinary expenses among other things Euro provisions for damage claims in connection with a lost patent +1.8 litigation in the market region Central Europe million Relief on earnings from the measurement of derivative financial Euro instruments under financial income and expenses -1.5 million Total one-time effects Euro 37.0 million Net income, adjusted Euro 136.1 million </pre> Additional information for analysts: STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / e-mail: communications@stada.de Additional information for journalists: STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / e-mail: press@stada.de Or visit us in the Internet at www.stada.com. --------------------------------------------------------------------- 13.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel Germany Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: communications@stada.de Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard); Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 296679 13.11.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 72

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 72

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 135

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 69

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 95

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 34

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 93

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 46

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
AutoMobility LA Puts 2028 Mobility on Center Stage

Updated Category News Views 38

Los Angeles is cramming an awful lot of automotive ambition into one Thursday. AutoMobility LA opens November 19 at the Los Angeles Convention Center, one day before the LA Auto Show begins its November 20–29 public run. Yes, there will be coffee carts, awards, creators and the usual event confetti. But beneath that polished show-floor racket sits a fairly serious...

Continue Reading

Top 5 Most Recently Viewed Articles

Easterly ROCMuni Bond Fund Faces Investigation for Misconduct

Updated Category News Views 327

Investigation of Easterly ROCMuni High Income Bond Fund Investors of the Easterly ROCMuni High Income Municipal Bond Fund are facing troubling times. Recently, the Portnoy Law Firm initiated an investigation regarding potential securities fraud associated with this investment vehicle. If you have lost money after investing in the Easterly ROCMuni High Income, it's...

Continue Reading
Japan's Economic Transformation: Unleashing Investment Potential

Updated Category News Views 271

Understanding the Shift in Japanese Equities Japanese equities are experiencing a resurgence, and this transformation is hard to ignore. The landscape of investment in Japan is shifting rapidly, and for those keeping an eye on the developments, there are compelling reasons to be optimistic. For years, conventional thought had deemed Japan as a country facing overwhelming...

Continue Reading
Pet Grooming Services Market Growth Driven by Humanization Trends

Updated Category News Views 129

Exploring the Pet Grooming Services Market Growth The pet grooming services market is witnessing a remarkable transformation, with anticipated growth projected to reach over USD 12.05 billion during the next decade. The rising phenomenon of pet ownership, coupled with the ongoing trend of humanization, is significantly influencing this expansion. The global market was...

Continue Reading
Investors Unite Against Dow Inc. in Class Action Suit

Updated Category News Views 181

Class Action Lawsuit Filed Against Dow Inc. Pomerantz LLP has announced the filing of a significant class action lawsuit against Dow Inc. (NYSE: DOW) and certain high-ranking officials within the company. This legal move signals a definitive call to action for investors who may have been adversely affected by the company’s alleged misrepresentations and omissions...

Continue Reading
Innovative Philanthropy: A New Challenge for MrBeast

Updated Category News Views 505

Revolutionizing Philanthropy: A New Challenge for MrBeast In an exciting initiative that aims to transform the landscape of modern philanthropy, the 144K Collective has reached out to the well-known YouTube personality and philanthropy leader Jimmy Donaldson, popularly known as MrBeast. This event, titled "144K Vs. The Beast," represents a novel approach to enhancing...

Continue Reading